Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + eribulin + gemcitabine + paclitaxel + albumin paclitaxel
- Development stage
- Unknown
- Lead developer
- Johns Hopkins Medicine
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of standard-of-care chemotherapy agents used as the 'Investigator's Choice' comparator arm in clinical trials for breast cancer, such as the Phase 3 study of the HER2-targeted ADC BL-M07D1. This set includes capecitabine (an oral fluoropyrimidine carbamate), eribulin (a non-taxane microtubule dynamics inhibitor), gemcitabine (a pyrimidine antimetabolite), paclitaxel (a taxane microtubule stabilizer), and albumin-bound paclitaxel (a nanoparticle formulation of paclitaxel). These agents represent diverse mechanisms of action, including DNA synthesis inhibition and microtubule disruption, and are selected based on physician discretion for patients with recurrent or metastatic HER2-low breast cancer.
- Brand names
- Abraxane
- Other names
- nab-paclitaxelInvestigator's Choice Chemotherapy
02
Targets
TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))RNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on capecitabine + eribulin + gemcitabine + paclitaxel + albumin paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + eribulin + gemcitabine + paclitaxel + albumin paclitaxel.